Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.600 CHF
−54.04 M CHF
4.97 M CHF
33.00 M
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Founded
2004
ISIN
CH0256379097
FIGI
BBG00JYV5TW8
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 0QXX is 3.755 CHF — it has decreased by −4.68% in the past 24 hours. Watch MOLECULAR PARTNERS AG CHF0.1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange MOLECULAR PARTNERS AG CHF0.1 stocks are traded under the ticker 0QXX.
0QXX stock has fallen by −9.61% compared to the previous week, the month change is a −18.35% fall, over the last year MOLECULAR PARTNERS AG CHF0.1 has showed a 3.73% increase.
We've gathered analysts' opinions on MOLECULAR PARTNERS AG CHF0.1 future price: according to them, 0QXX price has a max estimate of 15.00 CHF and a min estimate of 6.00 CHF. Watch 0QXX chart and read a more detailed MOLECULAR PARTNERS AG CHF0.1 stock forecast: see what analysts think of MOLECULAR PARTNERS AG CHF0.1 and suggest that you do with its stocks.
0QXX reached its all-time high on Jan 14, 2022 with the price of 28.850 CHF, and its all-time low was 3.040 CHF and was reached on Oct 27, 2023. View more price dynamics on 0QXX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0QXX stock is 2.26% volatile and has beta coefficient of −0.23. Track MOLECULAR PARTNERS AG CHF0.1 stock price on the chart and check out the list of the most volatile stocks — is MOLECULAR PARTNERS AG CHF0.1 there?
Today MOLECULAR PARTNERS AG CHF0.1 has the market capitalization of 140.49 M, it has decreased by −9.18% over the last week.
Yes, you can track MOLECULAR PARTNERS AG CHF0.1 financials in yearly and quarterly reports right on TradingView.
MOLECULAR PARTNERS AG CHF0.1 is going to release the next earnings report on May 15, 2025. Keep track of upcoming events with our Earnings Calendar.
0QXX earnings for the last quarter are −0.30 CHF per share, whereas the estimation was −0.39 CHF resulting in a 23.08% surprise. The estimated earnings for the next quarter are −0.37 CHF per share. See more details about MOLECULAR PARTNERS AG CHF0.1 earnings.
MOLECULAR PARTNERS AG CHF0.1 revenue for the last quarter amounts to 0.00 CHF, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0QXX net income for the last quarter is −11.23 M CHF, while the quarter before that showed −16.40 M CHF of net income which accounts for 31.53% change. Track more MOLECULAR PARTNERS AG CHF0.1 financial stats to get the full picture.
No, 0QXX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 13, 2025, the company has 174.00 employees. See our rating of the largest employees — is MOLECULAR PARTNERS AG CHF0.1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MOLECULAR PARTNERS AG CHF0.1 EBITDA is −58.85 M CHF, and current EBITDA margin is −1.18 K%. See more stats in MOLECULAR PARTNERS AG CHF0.1 financial statements.
Like other stocks, 0QXX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULAR PARTNERS AG CHF0.1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MOLECULAR PARTNERS AG CHF0.1 technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MOLECULAR PARTNERS AG CHF0.1 stock shows the sell signal. See more of MOLECULAR PARTNERS AG CHF0.1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.